Mode
Text Size
Log in / Sign up

Sugammadex reduces recovery time after surgery by 6.66 minutes compared to anticholinesterase agentsSugammadex May Help Patients Recover Faster After Surgery

AI-generated summary of the cited source, checked by automated accuracy review. How we work

Key Takeaway
Note that sugammadex reduces recovery time after surgery by 6.66 minutes compared to anticholinesterase agents.

This meta-analysis evaluated the effectiveness, postoperative recovery, and complications associated with sugammadex compared to conventional anticholinesterase agents (e.g., neostigmine) in 4,082 adult surgical patients. The analysis synthesized data from several studies to compare outcomes such as recovery time, neuromuscular function, and postoperative complications.

Key findings include a reduction in recovery time after surgery by 6.66 minutes (MD -6.66; 95% CI -6.96 to -6.35) in 3 studies (n = 260). While a faster recovery of neuromuscular function was noted in 2 studies, high heterogeneity (I2 = 100%) was reported. Other outcomes, including PACU stay, readmission rate, and nausea and vomiting, showed no differences. Regarding postoperative pulmonary complications, no statistically significant reduction was found (OR 0.75; 95% CI 0.47 to 1.20; p = 0.23) in 3 studies (n = 688).

The authors note several limitations, including a small number of clinically heterogeneous studies and the inclusion of only 2 to 4 studies for some specific outcomes. Due to these factors, the results are considered preliminary. Clinical application should be interpreted with caution given the heterogeneity of the underlying data.

How this fits prior evidence

This meta-analysis extends previous evidence regarding sugammadex as a reversal agent. It builds upon findings that sugammadex selectively reverses rocuronium blockade within 3 minutes and its potential respiratory benefits in morbidly obese patients. While previous reports highlighted specific benefits in morbidly obese patients, this meta-analysis provides a broader look at recovery times and pulmonary complications in a larger sample of 4,082 adult surgical patients.

Researchers analyzed data from over 4,000 adult surgical patients to compare two types of medications used to reverse the effects of muscle relaxants. One medication is sugammadex, while the other is a traditional anticholinesterase agent like neostigmine. The goal was to see which drug helped patients recover more effectively after surgery.

The analysis found that patients who received sugammadex experienced a faster recovery of neuromuscular function and a reduction in overall recovery time after surgery. Some evidence also suggested an earlier return of bowel function. However, the study did not find significant differences between the two drugs regarding nausea, vomiting, hospital readmission rates, or time spent in the recovery room.

It is important to note that these results are preliminary. The researchers used a small number of studies that were quite different from one another. Because the evidence is limited and the data is not yet fully consistent, these findings should be viewed as early indicators rather than a definitive rule for all patients.

What this means for you:
Sugammadex may offer faster recovery times after surgery, but more consistent data is needed to confirm these results.

Common questions

How does sugammadex compare to traditional drugs like neostigmine?

In this study of 4,082 patients, sugammadex was linked to faster recovery of neuromuscular function and shorter recovery times after surgery. However, there were no significant differences found between the two drugs regarding nausea, vomiting, or the length of stay in the post-anesthesia care unit.

Does sugammadex reduce complications like nausea or vomiting?

The study did not find any statistically significant difference between sugammadex and traditional anticholinesterase agents regarding nausea or vomiting. Other factors, such as readmission rates and time spent in the recovery room, also showed no significant differences between the two treatments.

Is the evidence for sugammadex's effectiveness certain?

The results are currently considered preliminary. The researchers noted that the study relied on a small number of diverse studies, which makes it difficult to draw firm conclusions. You should speak with your doctor to discuss which medication is best for your specific surgical needs.

Study Details

Study typeMeta analysis
EvidenceLevel 1
PublishedOct 2026
View Original Abstract ↓
Residual neuromuscular blockade after general anaesthesia is a cause of postoperative pulmonary complications and delayed recovery. Sugammadex, a relaxant-binding agent, is a fast-acting antidote for aminosteroid neuromuscular block which works through encapsulation, in contrast to acetylcholinesterase inhibitors like neostigmine. This study evaluated the effectiveness, postoperative recovery and complications associated with sugammadex versus conventional anticholinesterase reversal drugs in adult surgical patients. This systematic review and meta-analysis was done based on the PRISMA 2020 statement. Databases like PubMed/MEDLINE and Scopus were used to search the literature from January 2000 to December 2025. Studies comparing the use of sugammadex to anticholinesterase agents in adult surgical patients were included, both randomised and non-randomised. Two independent reviewers screened, extracted data and assessed the risk of bias. Analyses were carried out in RevMan 5.3 software using random-effect models; the odds ratio (OR) for dichotomous outcomes and the mean difference (MD) for continuous outcomes were used with 95% confidence intervals (CI). Evidence certainty was assessed using the GRADE approach. Total of ten studies (n = 4,082) were included; 5 randomised control trials and 5 observational studies. There was no statistically significant reduction in postoperative pulmonary complications with sugammadex compared to anticholinesterase (3 studies, n = 688; OR 0.75, 95% CI 0.47–1.20; p = 0.23; I2 = 77%). There was faster recovery of neuromuscular function with sugammadex, however, there was very high heterogeneity among the studies and the pooled estimate cannot be interpreted as one single effect size (2 studies; I2 = 100%). Recovery time after surgery was reduced (3 studies, n = 260; MD -6.66 min, 95% CI −6.96 to −6.35; p  Faster neuromuscular recovery, shorter recovery time after surgery and early return of bowel function was associated with the use of sugammadex rather than the anticholinesterase agents. There were no differences found for postoperative pulmonary complications, PACU stay, readmission rate or nausea and vomiting. These results are based on small number of clinically heterogeneous studies, in which only 2–4 studies were used in pooling and thus should be considered as preliminary results.
Free Newsletter

Clinical research that matters. Delivered to your inbox.

Join thousands of clinicians and researchers. No spam, unsubscribe anytime.